Core Viewpoint - MIRXES-B, a company focused on RNA technology, successfully listed on the Hong Kong Stock Exchange on May 23, with an initial price of 23.3 HKD, experiencing a significant opening increase of 24.89% to reach 29 HKD, and closing at 29.9 HKD, resulting in a total market capitalization of 82.62 billion HKD [1][2]. Company Overview - MIRXES-B was founded in 2014 in Singapore by Zhu Xingfen, Zhou Lihan, and Zou Ruiyang, focusing on developing blood-based miRNA testing kits for early disease detection globally [3][4]. - The company's core product, GASTROClearTM, is the first and only regulatory-approved molecular IVD product for gastric cancer screening, characterized by its non-invasive, rapid, and convenient features [3][4]. Financial Performance - The company reported revenues of 17.76 million USD, 24.18 million USD, and 20.28 million USD for the years 2022, 2023, and 2024, respectively, with gross profits of 9.33 million USD, 13.58 million USD, and 8.89 million USD during the same period [5]. - However, the company also faced increasing losses, reported at 56.20 million USD, 69.57 million USD, and 92.21 million USD for the same years [5]. Investment and Funding - The IPO attracted significant cornerstone investors, including Beijing Xunrui and Evergreen Gate, who collectively subscribed to shares worth 57.92 million USD, with Beijing Xunrui investing 50 million USD and Evergreen Gate investing 7.92 million USD [3]. - Notably, Sun Tongyu, former president of Taobao, played a crucial role in the company's funding, having invested 4 million SGD (approximately 2.8 million USD) in 2016 and later participating in a 30 million USD Series B funding round [4]. - Following the IPO, Sun Tongyu's stake in MIRXES-B is valued at approximately 1.839 billion HKD, reflecting a 7x return on investment [4].

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing up 0.24% at 23,601.26 points, while the Hang Seng Tech Index fell 0.09% to 5,246.87 points. The total trading volume for the day was HKD 203.67 billion [1] - For the week, the Hang Seng Index rose 1.1%, while the Hang Seng China Enterprises Index increased by 1.36%, and the Hang Seng Tech Index declined by 0.65% [1] Blue-Chip Stocks Performance - BYD Company (01211) reached a new high, closing up 1.97% at HKD 465.2, contributing 18.25 points to the Hang Seng Index. The company reported a 169% year-on-year increase in electric vehicle registrations for April [2] - Other notable blue-chip stocks included CSPC Pharmaceutical Group (01093) up 2.16%, WH Group (00288) up 2.16%, while Chow Tai Fook (01929) fell 3.32% [2] Sector Highlights - The pharmaceutical sector saw significant gains, with Hengrui Medicine (noted for its IPO) surging over 25% on its debut, reflecting strong market confidence [3][4] - Gold stocks turned positive in the afternoon, with Lingbao Gold (03330) rising 9.16% and other gold-related stocks also showing gains [4][5] - The automotive sector experienced an upward trend, with BYD and Great Wall Motors (02333) both reporting increases in stock prices [5][6] New Listings - Hengrui Medicine (01276) debuted strongly, closing up 25.2% at HKD 55.15, with a total issuance of 225 million shares and net proceeds of approximately HKD 9.75 billion [10] - MIRXES-B (02629) also performed well, closing up 28.76% at HKD 30, with net proceeds of about HKD 880 million from its share issuance [11]

Group 1 - The company MIRXES-B (02629) plans to conduct an initial public offering (IPO) from May 15 to May 20, 2025, with a total of 46.62 million shares being offered globally, where 10% is allocated for Hong Kong and 90% for international markets [1] - The offering price is set at HKD 23.30 per share, with trading expected to commence on May 23, 2025, at 9:00 AM on the Hong Kong Stock Exchange [1] - Founded in 2014 and headquartered in Singapore, the company specializes in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [1] Group 2 - The estimated net proceeds from the global offering, calculated at the offering price of HKD 23.30 per share, will be approximately HKD 880.5 million [2] - The intended use of the net proceeds includes 51% for research and development, regulatory filings, production, and commercialization of the core product GASTROClearTM; 24% for ongoing and planned R&D for pipeline products; 15% to enhance and integrate the company's end-to-end capabilities; and 10% for working capital and general corporate purposes [2] - The company has entered into cornerstone investment agreements with Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, with cornerstone investors agreeing to subscribe for USD 57.92 million under certain conditions [2]

Summary of Key Points Core Viewpoint The Hong Kong IPO market has seen significant activity from May 5 to May 11, with 8 companies submitting applications, 3 companies passing hearings, 1 company going public, and 3 companies listing. Group 1: IPO Applications - A total of 8 companies submitted IPO applications, including Zhongqi Yunlian, MIRXES, YS Intelligent, Xidi Zhijia, Tong Shifu, Zhejing Electronics, Zhongding Integration, and Fuyou Payment [2][3] - Zhongqi Yunlian, established in 2015, is a leading independent digital financial platform in China, with a projected revenue of 6.52 billion RMB in 2022, increasing to 9.91 billion RMB by 2024 [3] - MIRXES, founded in 2014, specializes in miRNA technology for disease screening, with projected revenues of approximately 177.59 million USD in 2022, growing to 202.83 million USD by 2024 [4][5] - YS Intelligent, focusing on AI-driven pharmaceutical solutions, has raised over 500 million USD from notable investors and has a post-money valuation of 1.33 billion USD [6] - Xidi Zhijia, a provider of autonomous driving solutions, reported revenues of 310.56 million RMB in 2022, expected to reach 410 million RMB by 2024 [7] - Tong Shifu, established in 2013, leads the copper cultural products market in China with a 35% market share, projecting revenues of 503 million RMB in 2022 [8] - Zhejing Electronics, a pioneer in smart cockpit solutions, reported revenues of approximately 214 million RMB in 2022, with expectations of growth [9] - Zhongding Integration, a provider of smart logistics solutions, reported revenues of approximately 1.643 billion RMB in 2022, with a projected increase [11] - Fuyou Payment, a digital payment technology platform, reported revenues of approximately 1.142 billion RMB in 2022, with growth anticipated [12] Group 2: Companies Passing Hearings - Heng Rui Pharmaceutical, a leading innovative pharmaceutical company, reported revenues of 21.275 billion RMB in 2022, expected to grow to 27.985 billion RMB by 2024 [13][14] - Ningde Times, a leader in battery manufacturing, is expected to raise between 4 billion to 5 billion USD in its IPO, with a market share of 37.9% in the global battery market by 2024 [15][16] - Jihong Co., a dual-driven company in cross-border e-commerce and paper packaging, reported revenues of 5.376 billion RMB in 2022, with growth expected [17] Group 3: IPO and Listings - Green Tea Group is set to launch its IPO, offering 168 million shares at a price of 7.19 HKD per share, with significant interest from cornerstone investors [18] - Boleton, listed on May 7, priced at 18 HKD per share, saw a closing price of 24.9 HKD, reflecting a 38% increase [19] - Hu Shang Ayi, listed on May 8, had an opening price of 190.6 HKD, closing at 158.4 HKD, a 40.03% increase from its issue price [20] - Jun Da Co., also listed on May 8, opened at 22.2 HKD and closed at 26.6 HKD, marking a 20.09% increase [20] Group 4: Market Developments - The Hong Kong Stock Exchange has launched a "Tech Company Fast Track" to facilitate IPO applications for technology and biotech companies, allowing for confidential submissions [21]

Core Viewpoint - Mirxes Holding Company Limited is seeking to list on the Hong Kong Stock Exchange, with CICC and CCB International as joint sponsors [1] Company Overview - Founded in 2014, Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology aimed at making disease screening and diagnostic solutions accessible in key Asian markets, including Singapore and China [3] - The company has one core product, GASTROClearTM, which is the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [3] Market Opportunity - Gastric cancer is the fifth leading cause of cancer death globally in 2023, with approximately 1 million new cases [3] - The gastric cancer screening market in China, Japan, Southeast Asia, and the United States grew from $13 billion in 2019 to $15.2 billion in 2023, with a compound annual growth rate (CAGR) of 4.1% [3] - The market is projected to reach $21.2 billion by 2028 and $25.4 billion by 2033, with CAGRs of 6.8% and 3.7% respectively for the periods 2023-2028 and 2028-2033 [3] Financial Performance - Revenue for 2022, 2023, and 2024 is estimated at approximately $17.76 million, $24.19 million, and $20.28 million respectively [4] - Gross profit for the same years is estimated at about $9.33 million, $13.58 million, and $8.89 million [4] - The company has incurred significant operating losses, with a projected loss of approximately $56.2 million in 2022, $69.57 million in 2023, and $92.21 million in 2024 [6]

Company Overview - Mirxes Holding Company Limited, founded in 2014 and headquartered in Singapore, specializes in microRNA (miRNA) technology for disease screening and diagnostic solutions in key Asian markets, including Singapore and China [5][6] - The company has one core product, GASTROClear™, and two other commercialized products, LUNGClear™ and Fortitude™, along with six candidates in preclinical stages [5] Product Details - GASTROClear™ is a blood-based miRNA test kit for gastric cancer screening, consisting of 12 miRNA biomarkers. It received regulatory approval from the Health Sciences Authority (HSA) in Singapore in May 2019 and has been successfully commercialized [5][6] - The company is one of the few globally to have regulatory approval for molecular cancer screening IVD products and is the first and only company to receive such approval for molecular gastric cancer screening [5] Market Position - Mirxes operates within the liquid biopsy subcategory of the overall disease screening market, focusing on non-invasive, affordable, and effective blood-based miRNA test kits for early cancer detection [6] - The company’s core product, GASTROClear™, is part of a growing trend in molecular diagnostics, utilizing liquid samples to detect cancer biomarkers [6] Financial Performance - The company reported revenues of approximately $17.76 million, $24.19 million, and $20.28 million for the years 2022, 2023, and 2024, respectively [6][7] - Gross profits for the same years were approximately $9.33 million, $13.58 million, and $8.89 million, indicating a gross margin of 52.5%, 56.2%, and 43.8% respectively [7]